biotech Over the course of a day of unprecedented collaboration, Argentina’s biotech industry came together to discuss the challenges facing their industry in Argentina and the region at BioArgentina 2014, an event organized by the Argentinian Chamber of Biotechnology (CAB). Bringing together over 900 professionals across the industry, with perspectives from the…
biotech The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million since 2006, and strives to deliver its pipeline of innovative medicines to treat seriously ill patients in Mexico. You…
biotech The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came into life, the lack of culture at Mexican universities of filing patents for academic research and the potential of the…
cardiology The general manager of Argentia weighs up the factors that have led to his company consolidating its different business lines and becoming one of the fastest growing companies in Argentina. What was your main objective upon joining Argentia? In 1995, Argentia was acquired by BMS and was sold to…
innovation Hugo Sigman explains how understanding problems in the same way as opportunities helped his company to become what is today, a successful Argentinian conglomerate where life and science is the backbone of multiple businesses. Please start by describing the Insud group as it stands today, and where it operates.…
biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector. How did you become involved with Bioceres? I have known the…
biotech For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments by Spain’s government. Regina Revilla, president of Spain’s biotech association ASEBIO, details the history of biotech in Spain and outlines…
amgen Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more sustainable health ecosystem for the future of Spain. You became general manager of Amgen Iberia in 2012, in the middle…
Cell2B David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice. What do you see as Portugal’s capacity for the local life sciences industry to grow? DM: Portugal is one of the best-positioned…
Biotechnology Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming a critical factor for sustainable growth.” Despite the fact that the Polish business environment has changed significantly, access to innovation…
See our Cookie Privacy Policy Here